Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
765.810.53%
QQQ
709.410.25%
BTC/USD
77463.050.0911%
DIA
530.290.48%
GLD
400.891.04%
TLT
81.780.1%

Definium Therapeutics Inc

DFTXNASDAQ
Trade with Public
Trade with Public
$38.38
-0.12-0.3%
Last update: Sep 2, 12:07 PM
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Definium Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Definium Therapeutics (DFTX).

Price Target Range — 3 Quarters

Analyst Consensus — 15 Analysts

15Buy
Consensus RatingBuy# Analysts15Avg. Consensus PT$62Upside to Avg. PT+62.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 18, 2026B of A SecuritiesTazeen AhmadInitiateBuy$75
Aug 14, 2026Maxim Group—PT RaiseBuy$50→$55
More with Benzinga EdgeGet Access

Analyst Ratings News

This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top analysts changed outlook on top names. See analyst ratings page for all changes.
Avi Kapoor

PRO
B of A Securities Initiates Coverage On Definium Therapeutics with Buy Rating, Announces Price Target of $75

B of A Securities analyst Tazeen Ahmad initiates coverage on Definium Therapeutics (NASDAQ:DFTX) with a Buy rating and announces Price Target of $75.
Benzinga Newsdesk

PRO
Maxim Group Maintains Buy on Definium Therapeutics, Raises Price Target to $55

Maxim Group maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $50 to $55.
Benzinga Newsdesk

PRO
Jones Trading Maintains Buy on Definium Therapeutics, Raises Price Target to $90

Jones Trading analyst Justin Walsh maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $74 to $90.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Definium Therapeutics, Raises Price Target to $64

Canaccord Genuity analyst Sumant Kulkarni maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $58 to $64.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Definium Therapeutics, Raises Price Target to $66

RBC Capital analyst Brian Abrahams maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform and raises the price target from $57 to $66.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved